Gene therapy restores vision in 6-year-old Saffie with rare blindness

Six-year-old Saffie Sandford can now see clearly in both daylight and after dark thanks to a one-time gene therapy that corrected a rare inherited form of blindness. Her family says everyday moments—like going trick-or-treating and dining out in the evening—have become possible again after years of watching her struggle with low-light vision.

Saffie, who lives in Stevenage, was born with Leber’s Congenital Amaurosis caused by mutations in the RPE65 gene, a condition both parents unknowingly carried. The treatment she received at Great Ormond Street Hospital is part of a growing wave of gene therapies aimed at correcting genetic causes of sensory loss in children.

How a single dose of gene therapy can restore vision

The therapy Saffie received, known commercially as Luxturna, delivers a healthy copy of the RPE65 gene directly into the retinal cells of each eye. Unlike ongoing medication or repeated procedures, this approach uses a single administration to enable retinal cells to process visual signals more normally.

• Target: RPE65 gene mutation that causes Leber’s Congenital Amaurosis (LCA).
• Delivery: one dose administered into each eye.
• Goal: restore the biochemical pathway that supports vision in low light and improve daytime peripheral sight.

What happened with Saffie: timeline and immediate effects

Saffie’s care pathway involved referral to Great Ormond Street Hospital after assessment at Moorfields Eye Hospital. She received the first eye dose in April 2025 and the second several months later in September. Within weeks of treatment her family noticed striking changes.

• April 2025: first Luxturna dose administered to one eye.
• September 2025: second dose completed to the other eye.
• Post-treatment: improved night vision, better peripheral awareness in daylight, and increased confidence in daily activities and at school.

Saffie’s mother described the difference as almost miraculous—nighttime activities that had once been impossible were now part of family life. School staff also reported that Saffie navigated hazards more safely and participated more fully in class.

Clinical data from children treated with Luxturna

Great Ormond Street Hospital, working with Moorfields, has published results from children treated with Luxturna, ranging from infants of 15 months to youngsters up to 12 years old. The outcomes point to meaningful visual improvements for many participants.

• Improvement rate: 7 out of 10 children showed clinically important gains in vision.
• Age range: patients as young as 15 months were included, highlighting the potential for very early intervention.
• Objective measurement: researchers used a novel, noninvasive test that records the electrical signals sent from the retina to the brain to evaluate visual pathway function in infants and toddlers.

According to consultants involved in the program, this objective electrical testing provides strong evidence that gene therapy can enhance the visual pathways of very young children with RPE65-LCA—changes that families can then see reflected in daily life.

Families’ experiences and real-world benefits

Beyond clinical scores, parents have reported clear differences in how their children engage with the world. For families coping with LCA, even modest visual gains translate to major quality-of-life improvements—safer mobility, more participation in after-dark activities, and fewer barriers at school.

• Everyday freedom: children can take part in evening events and better navigate their surroundings.
• Educational advantages: improved peripheral vision helps children detect hazards and engage more fully in classroom activities.
• Emotional impact: increased independence and confidence for both children and parents.

Gene therapy momentum: vision and hearing breakthroughs

The successful use of Luxturna for RPE65-related blindness fits into a broader trend of genetic treatments restoring sensory function. Separate trials in congenital deafness have reported strong outcomes, showing hearing restoration in pediatric patients treated with targeted gene therapy.

These parallel advances suggest a new era in pediatric care where single-dose genetic interventions can correct root causes of sensory disorders, offering durable improvements rather than temporary symptom management.

You might also like:

• CRISPR gene therapy baby thriving after world-first personalized treatment for rare disease
• Bubble boy disease: babies still appear cured after long-term follow-up
• Young boy with cancer raises $2,000, delivers 124 Easter baskets to kids in hospitals
• Cancer-fighting cells engineered in patients’ bodies for the first time
• If You Find The Only ‘9’ Among 150 ‘7’s, Your IQ Is Higher Than 97+

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.